China: Intellectual Property Issues of Biomedical Outsourcing in the PRC

Last Updated: 3 November 2012
Article by Qu Miao

As a result of the development of the biomedical industry and the Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) business models, China has become one of the most important outsourcing destination countries, acquiring considerable market share of the global outsourcing market. This paper aims to provide an overview of the intellectual property issues as related to biomedical outsourcing in the Chinese context.

I. Types of outsourcing and their respective legal relationships

In practice, there are many different types of possible relationships between pharmaceutical enterprises and CROs, for example: the revenue and risk sharing model, technology sharing model, cooperative management and development model, general research & development (R&D) model and technology service model. However, regardless of the type of commercial relationships or commercial terms the parties enter into, the legal status of the relationships will normally fall into one or more types of specific legal relationships. Therefore, how to define the specific legal relationship of an outsourcing model will affect the application of law, as well as the interpretation and execution of the contracts.

Under the PRC Contract Law i, the legal relationship between a pharmaceutical enterprise and a CRO usually falls within one of the following types: commissioned development, cooperative development, technical consultancy and technical services, and technology transfer. The biggest difference between commissioned development and cooperative development is the participation of R&D activities. In a commissioned development model, the commissioning party usually pays for all research and development expenses, as well as remuneration, and provides technical materials and original data, while the commissioned party completes the research and development. In a cooperative development model, the parties make their respective investments (including investments of technology), as well as collaborate in R&D activities according to the terms of the contract.

The legal relationships between pharmaceutical enterprises and CMOs normally fall under processing contracts (for relatively straightforward CMOs). Occasionally, the relationship may also be classified as technical consultancy and services or as commodity purchasing.

II. Intellectual Property issues pertinent to the outsourcing relationship

A. Ownership of Intellectual Property rights

Cooperating parties must make clear and detailed agreements during the negotiation process regarding ownership of intellectual property rights to avoid potential disputes.

First, the parties must clearly define the content, scope and boundaries of their respective intellectual property rights before executing any contracts. This may seem like a simple task, however, due to the unique nature of intangible assets and the frequency of information exchange, it is no small feat in practice. This imposes a higher daily management requirement on the party delivering the information and data.

Next, the parties need to explicitly agree on the ownership of any technical achievements as well as their respective rights regarding those results. If there is no express agreement in the contract, ownership of the technical achievements will be determined by the law under the following principles:

a. Commissioned development contracts

Under the Chinese legal framework, the ownership of any technical achievement arising from a commissioned development contract depends on the method by which the parties choose to protect the achievement. With respect to an invention created in a commissioned development, without an express agreement otherwise, the right to apply for a patent belongs to the research party, but the commissioning party may use the patent for free. In the event the research party transfers the right of patent application, the commissioning party shall have priority over transfer under the same conditions. However, if the technical achievements are technical secrets, then both parties have equal rights to use and license such secrets as under a general license, similar to that under co-ownership.

b. Cooperative development contracts

For any technical achievements developed under the cooperative development model, the right to apply for a patent will be owned by the parties jointly. If one party chooses to assign its application right, the other party enjoys priority to be assigned the right under the same conditions. If one party is unwilling to pay the application costs and waives its right to jointly apply for a patent, then the other party may apply for the patent independently; nonetheless, the waiving party may still be entitled to use the patent for free. It should be noted that if one party does not agree to apply for a patent, e.g. is unwilling to disclose the technology results, the other party will be unable to apply as well.

c. Technical consultancy and service contracts

Under the technical consultancy and service model, any technical achievements, accomplished by the CRO utilizing the technical materials and development facilities supplied by the pharmaceutical enterprise, shall belong to the CRO. However, any new developments, accomplished by the pharmaceutical enterprise using the results generated by the CRO, shall belong to the pharmaceutical enterprise.

Furthermore, if the parties do not set forth confidentiality obligations towards each other in the contract in respect of the technical materials and data provided by pharmaceutical enterprises as well as consultancy reports and opinions provided by CROs, and under the condition that exposure of such material will not cause due damage to the legitimate rights and interests of the parties, the parties shall be entitled to refer to, publish, and supply such information to the third parties.

It is therefore vital to set explicit terms regarding the ownership of any technical achievements as well as the rights enjoyed by the parties with respect to the achievements.

B. Identifying third-party rights

In addition to clearly defining the ownership of IP rights of both parties, the existence of third-party rights should also be evaluated to ensure the allocation of IP is valid and enforceable. Potential third parties include employees or research sub-contractors of CROs or third-party institutes assisting CROs.

CRO research is usually done by R&D fellows, who may be employees of CRO, employees of third-party institutes commissioned by a CRO, such as universities, hospitals and inspection institutes, or independent contractors who signed contracts with the CRO. In such cases, in order to ensure the allocation of IP rights between parties are enforceable, one should firstly ensure that the CRO is legally entitled to dispose of such technical achievements.

a. Statutory rights of CRO employees

CROs must explicitly stipulate in the employment contracts with its employees that all the inventions and technical achievements created by the employees belong to the CRO. However, CROs should also be aware that the employees, as developers of a technical achievement, enjoy a series of statutory rights:

  1. Under the Patent Law, an inventor or designer has the right to identify himself as the inventor or designer in the relevant patent documents; pharmaceutical enterprises particularly need to pay attention to this aspect when preparing filing documents and filing patent applications after obtaining the relevant technical achievements developed by CROs.
  2. Under the Contract Law, an individual who accomplishes a technical achievement is entitled to identify himself as the developer in the documentation related thereto, and to receive recognition and awards, as well as remuneration from his employer.
  3. Under the Contract Law, the individual who accomplishes the technical achievement shall have priority of assignment rights to the technical achievement under the same conditions.

Furthermore, CRO's should also be aware of the rights of third-party entities such as former employers of its employees referred to in section 2.2.3 of this article.

b. CRO's cooperative units and their staff

If the CRO further commissions third-party institutes or cooperates with them to jointly complete part of the research project, the CRO would also become a commissioning party or a cooperating party in the cooperative development relationship. The CRO itself should also make it clear regarding the ownership and/or limitations of the relevant IP rights in the contracts entered between the CRO and any third-party institutes.

In the case that the CRO fails to acquire sole ownership with complete, unlimited, and unimpeded rights by explicit provisions in the contract, due to either lack of awareness of the IP involved or contract management issues, the CRO would not be entitled to assign the IP rights of such technical achievements to the commissioning pharmaceutical enterprise. Even if the parties set forth in the cooperation contract explicit provisions regarding the assignment and disposal of such rights by the CRO, the CRO would still not be able to dispose the relevant property and rights as such provisions would be deemed invalid.

Furthermore, the CRO must also pay attention to any agreements entered into between the third-party institutes and their own employees or independent contractors. This is to ensure that the third-party institutes can legitimately dispose of any technical achievements without infringing others' rights and interests.

Thus it is possible that the pharmaceutical enterprisemay not be guaranteed all the rights provided for in the contract despite the must scrupulous contract negotiation and execution with the CRO due to unforeseeable issues which have occurred on the CRO side.

c. Independent contractors to CROs

Similarly, the CRO must also pay attention to the allocation of rights of any technical achievements and explicitly provide for such in its contracts with independent contractors. Such independent contractors also enjoy certain statutory inventor rights under the Patent law and the Contract law.

d. Former employers or commissioners of the employees of CROs or its independent contractors

The CRO must be aware of the rights of the former employers of its employees or contractors who worked on a similar subject matter previously.

  1. Under the PRC law, any technical achievements developed by a former employee within one year after leaving the employment on a topic related to those the employee had been engaging in his previous employment shall be deemed as work-related technical achievements. Such rights of use and assignment belong to his former employer.
  2. Under the PRC law, where a technical achievement is accomplished by an individual through performing his duties with his former employer, but using mainly the materials and development facilities provided by the CRO, the rights and interests shall be determined pursuant to the agreement between the former employer and the CRO. If an agreement cannot be reached, the rights and interests shall be shared by both parties on the basis of their contributions to the technical achievement.
  3. The former employer is entitled, pursuant to signed contracts, to forbid former employees, who have left their positions, from pursuing similar professions or trades in competition with the former employer after the termination of employment, and to bind former employees with confidentiality obligations.
  4. If independent contractors have worked for other institutes, the CRO must be aware of and seek to prevent contractors from using achievements the contractors have accomplished for the former employer as deliverables. The possession of certain technical achievements which actually belong to others will put the CRO at risk of infringement.

C. Protection and management of Intellectual Property

a. Choosing a method to protect technical achievements

Laws vary across jurisdictions, and this is a key factor for pharmaceutical enterprises to consider when determining the method by which to seek protection for IPR achieved through international outsourcing. For instance, with respect to patentable technical achievements, the PRC laws provide greater flexibility in terms of choosing the method of protection, that is, pharmaceutical enterprises can choose to protect technical achievements via trade secrets, and can amend them into patent applications at any time. In comparison, under the US laws, such alteration must be made within a certain time limit.

Furthermore, pharmaceutical enterprises should also ensure that the method with which they choose to protect technical achievements complies with the legal rules and practice in the relevant countries and jurisdictions. For instance, the standards of patentability of substantive examination of patent applications are different across different countries. Taking technical achievements regarding medical methods as an example, it is very difficult to obtain such patent grants in the PRC, whereas it is possible to do so in the US and other countries.

b. Preventing leaks of confidential information by CROs

Another challenging problem that pharmaceutical enterprises face is the leakage of information and the loss or publication of technical achievements by CROs. Provided that the CRO itself does not intentionally infringe or breach any contracts, leaks of confidential information are generally caused by third parties, such as loss of technical achievements by intentional or negligent conduct of employees, turnover, as well as willful theft by a third person.

Pharmaceutical enterprises should adopt preventative measures to prevent such leaks. In selecting CROs, pharmaceutical enterprises should consider factors such as internal management, sufficiency of employee IP awareness, adequacy of legal documents, and sufficiency of measures taken to safeguard sensitive information. Furthermore, pharmaceutical enterprises should be familiar with local laws, so as to be able to make prompt decisions in case of emergency.

It should also be noted that pharmaceutical enterprises and CROs should explicitly agree in contracts on items such as what legal measures may be taken in case of dispute, the governing law, and the bearer of any legal costs. It is particularly important with respect to technical achievements developed in partnership due to the uncertainty of allocation of rights, to agree beforehand on the right of first decision in case of emergency, to minimize delay.

Finally, given the fact that confidential leaks may involve CROs (their employees, or willful third parties), there may be more legal remedies available to the CRO as compared with the commissioning pharmaceutical enterprise. As such, even if the pharmaceutical enterprise is accorded the right of first decision, it's ideal to include explicit provisions regarding obligations to assist in the protection of IP, so as to allow for more potential remedies under local law.

c. Constructing patent applications with a global vision

In the process of cross-border outsourcing, not only do pharmaceutical enterprises need to consider how to maximize the outsourcing relationship's advantages, they need to be aware of the risks of cross-border outsourcing. Risks include mandatory regulations imposed on CROs and the applicable regulations and practices in the jurisdiction.

(i) Avoid choosing the PRC as the country of initial application for patents

PRC Patent Law expressly states that any entity seeking to apply for a patent with respect to an invention or utility model accomplished in the PRC shall first report the matter to the administrative department for patents under the State Council for a confidentiality examination. Therefore, even if pharmaceutical enterprises as commissioning parties wish to apply for patents for the technical achievements produced through outsourcing in their home country or jurisdictions other than the PRC for the initial application, they still need to abide by the confidentiality examination regulations under PRC law.

(ii) Genetic resource related research and development

Research and development making use of genetic resources should be in conformity with PRC law. PRC Patent Law expressly states that no patent right shall be granted for any invention-creation which is produced using genetic resources acquired or utilized in violation of any law or administrative regulations. Accordingly, the applicant must indicate the direct and original sources of the genetic resources used in application documents when applying for a patent.

(iii) Statements of patent application

A common mistake American pharmaceutical enterprises make is naming the patent inventor as "Assignor" when they apply for patents in the US. They also request that patent inventors directly sign a transfer agreement to obtain the right to patent application. Although this is common practice in the US, this practice violates PRC law. These actions may result in an invalid transfer and may even constitute a mistaken statement in the patent application process and ultimately affect the validity of patent. That is because according to PRC law, if a technical achievement is a service technical achievement, the employer is the legal owner of said technical achievement as opposed to the inventor. As such, the inventor has no right to sign such a transfer agreement with the American company.

(iv) Tax Consequences

Taxes are often another important factor considered in developing patenting strategies for technologies developed though outsourcing. Because of the general policy of encouraging inventions and creations, patent application may implicate preferential tax treatment by certain governments. Determining the most effective patent application strategy, especially when technical achievements are produced in different countries and jurisdictions, usually requires a comprehensive analysis and implementation scheme supported by a team of professionals.

III. Other legal issues pertinent to outsourcing relationships

A. Technological monopolies

The PRC has not published any specialized guidelines directed at antitrust issues arising from technology transactions. However the Contract Law provides several prohibitions. The following restraints may be deemed to monopolize a technology market, rendering such contracts invalid: (1) Restricting one party from making further research based on the technology subject to the contract, or restricting one party from using such improved technology, or providing disparate terms of exchange for any improved technologies between the parties, such as requiring one party to gratuitously provide the other party with the improved technology, or to unilaterally transfer the improved technology to the other party, or requiring sole or joint ownership of IP rights of the improved technology without consideration; (2) Restricting one party from obtaining, from other sources, technologies similar to or competitive with that of the technology provider; (3) Impeding one party's reasonable exploitation of the technology subject to contract pursuant to the market demands, such as unreasonably restricting the quantity, varieties, price, sales channel or export market of products or services based on the technology subject to contract; (4) Requiring the technology accepter to accept unnecessary conditions relevant to exploiting the technology, including purchasing unnecessary technologies, raw materials, products, equipment, services and accepting unnecessary persons, etc.; (5) Unreasonably restricting the technology accepter's channels or sources of raw materials, parts and components, products or equipment, etc.; and (6) Prohibiting the technology accepter from making objections regarding the validity of the IP rights of the technology subject to contract, or imposing conditions to any objections made.

Although these prohibitions are more relevant to technology transactions and licensing agreements, they may be involved in CRO outsourcing relationships, especially the first restraint.

B. Technology import/export control

The PRC controls the import and export of technology. Specifically speaking, technologies are categorized as free export technologies, restricted export technologies and prohibited export technologies. Pharmaceutical enterprises should be aware of these regulations prior to working with CROs in order to avoid to violating any regulations.

In addition, even in the case of free export technologies, contracts must be submitted for registration formalities with the commercial department or local ministry of foreign trade and economic cooperation. Even though a contract will not be invalidated due to failure to comply with registration formalities it may affect a party's ability to collect payment or obtain tax benefits.

IV. Conclusion

China is an attractive market with a unique legal system. However, companies that choose China as an outsourcing destination should obtain information about local relevant laws at an early stage to establish the right legal relationships, protect property rights, and reduce the risk of future conflicts and delays.


i The PRC Contract Law was adopted at the Second Session of the Ninth National People's Congress on March 15, 1999, and became effective as of October 1, 1999.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.